{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:38:38Z","timestamp":1787236718466,"version":"build-2736575974"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014034","name":"Foundation for Research in Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014034","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Psoriatic arthritis (PsA) is a chronic inflammatory joint disease within the spondyloarthritis spectrum. IL-12p40\/IL-23p40 blockade reduces PsA disease activity, but its impact on synovial inflammation remains unclear.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objectives:<\/jats:bold>\n                    To investigate the cellular and molecular pathways affected by IL-12p40\/IL-23p40 blockade with ustekinumab in the synovium of PsA patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Eleven PsA patients with at least one inflamed knee or ankle joint were included in a 24-week single-center open-label study and received ustekinumab 45 mg\/sc according to standard care at week 0, 4, and 16. Besides clinical outcomes, synovial tissue (ST) samples were obtained by needle arthroscopy from an inflamed knee or ankle joint at baseline, week 12 and 24 and analyzed by immunohistochemistry, RNA-sequencing and real-time quantitative polymerase chain reaction (qPCR).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    We obtained paired baseline and week 12, and paired baseline, week 12 and 24 ST samples from nine and six patients, respectively. Eight patients completed 24 weeks of clinical follow-up. At 12 weeks 6\/11 patients met ACR20, 2\/11 met ACR50 and 1\/11 met ACR70 improvement criteria, at 24 weeks this was 3\/8, 2\/8 and 1\/8 patients, respectively. Clinical and serological markers improved significantly. No serious adverse events occurred. We observed numerical decreases of all infiltrating cell subtypes at week 12, reaching statistical significance for CD68+ sublining macrophages. For some cell types this was even more pronounced at week 24, but clearly synovial inflammation was incompletely resolved. IL-17A and F, TNF, IL-6, IL-8, and IL-12p40 were not significantly downregulated in qPCR analysis of W12 total biopsies, only MMP3 and IL-23p19 were significantly decreased. RNA-seq analysis revealed 178 significantly differentially expressed genes between baseline and 12 weeks (FDR 0.1). Gene Ontology and KEGG terms enrichment analyses identified overrepresentation of biological processes as response to reactive oxygen species, chemotaxis, migration and angiogenesis as well as MAPK-ERK and PI3K-Akt signaling pathways among the downregulated genes and of Wnt signaling pathway among the upregulated genes. Furthermore, ACR20 responders and non-responders differed strikingly in gene expression profiles in a\n                    <jats:italic>post-hoc<\/jats:italic>\n                    exploratory analysis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Ustekinumab suppresses PsA synovial inflammation through modulation of multiple signal transduction pathways, including MAPK-ERK, Wnt and potentially PI3K-Akt signaling rather than by directly impacting the IL-17 pathway.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2021.611656","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T10:55:37Z","timestamp":1614855337000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["IL-12p40\/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt"],"prefix":"10.3389","volume":"12","author":[{"given":"Ren\u00e9e H.","family":"Fiechter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri\u00ebtte M.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonieke J. J.","family":"van Mens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inka A.","family":"Fluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander W.","family":"Tas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique L. P.","family":"Baeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya G.","family":"Yeremenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen G. H.","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/jid.2008.233","article-title":"Genetic variants of the IL-23R pathway: Association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis","volume":"129","author":"H\u00fcffmeier","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S778","DOI":"10.1136\/annrheumdis-2020-217163","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, m","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: Results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","article-title":"Ustekinumab, an anti-IL-12\/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-c","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1002\/art.20477","article-title":"Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor \u03b1 blockade in spondylarthropathy","volume":"50","author":"Vandooren","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1136\/annrheumdis-2012-203155","article-title":"Peripheral joint inflammation in early onset spondyloarthritis is not specifically related to enthesitis","volume":"73","author":"Paramarta","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/rheumatology\/kev330","article-title":"Immunopathology of synovitis: from histology to molecular pathways","volume":"55","author":"van de Sande","year":"2016","journal-title":"Rheumatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/art.40581","article-title":"Brief report: interleukin-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses","volume":"70","author":"van Mens","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1136\/ard.2008.091389","article-title":"A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: Effects of adalimumab treatment on synovial tissue","volume":"68","author":"Van Kuijk","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"R326","DOI":"10.1186\/ar1182","article-title":"Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study","volume":"6","author":"Goedkoop","year":"2004","journal-title":"Arthritis Res Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/ard.2003.018549","article-title":"Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy","volume":"64","author":"Kruithof","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/ard.2010.139550","article-title":"Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials","volume":"70","author":"Van De Sande","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: A Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2009","journal-title":"Bioinformatics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat Protoc."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1136\/annrheumdis-2016-210424","article-title":"Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?","volume":"76","author":"Alivernini","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/art.21914","article-title":"Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis","volume":"54","author":"Kruithof","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1136\/annrheumdis-2013-204229","article-title":"High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission","volume":"74","author":"Araujo","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40265-018-0994-3","article-title":"Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity","volume":"78","author":"Ye","year":"2018","journal-title":"Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-019-1998-4","article-title":"Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial","volume":"21","author":"De Jong","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/j.jaci.2018.11.042","article-title":"Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab","volume":"143","author":"Visvanathan","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41385-019-0212-y","article-title":"Interleukin-7 protects against bacterial respiratory infection by promoting IL-17A-producing innate T-cell response","volume":"13","author":"Hassane","year":"2020","journal-title":"Mucosal Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","article-title":"IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis","volume":"75","author":"Gracey","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3389\/fimmu.2018.01550","article-title":"The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling","volume":"9","author":"van Tok","year":"2018","journal-title":"Front Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blindplacebo- controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"10723","DOI":"10.1073\/pnas.1307569110","article-title":"Langerinneg conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice","volume":"110","author":"Wohn","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B34","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/mi.2015.65","article-title":"CD11c+ monocyte\/macrophages promote chronic Helicobacter hepaticus-induced intestinal inflammation through the production of IL-23","volume":"9","author":"Arnold","year":"2016","journal-title":"Mucosal Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"R359","DOI":"10.1186\/ar1501","article-title":"Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy","volume":"7","author":"Baeten","year":"2005","journal-title":"Arthritis Res Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/art.39469","article-title":"Dynamic contrast-enhanced magnetic resonance imaging using pharmacokinetic modeling: initial experience in patients with early arthritis","volume":"68","author":"Maijer","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1038\/onc.2012.478","article-title":"MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors","volume":"32","author":"Kitamoto","year":"2013","journal-title":"Oncogene"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1002\/art.20181","article-title":"Antiangiogenic effects of anti-tumor necrosis factor \u03b1 therapy with infliximab in psoriatic arthritis","volume":"50","author":"Ca\u00f1ete","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B39","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/art.37704","article-title":"Disease-specific and inflammation-independent stromal alterations in spondylarthritis synovitis","volume":"65","author":"Yeremenko","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B40","first-page":"631","volume-title":"Effects of the IL-23\u2013IL-17 Pathway on Bone in Spondyloarthritis","author":"Gravallese","year":"2018"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e0128262","DOI":"10.1371\/journal.pone.0128262","article-title":"Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis","volume":"10","author":"Dolcino","year":"2015","journal-title":"PLoS ONE"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1242\/dev.02471","article-title":"Wnt9a signaling is required for joint integrity and regulation og lhh during chondrogenesis","volume":"133","author":"Sp\u00e4ter","year":"2006","journal-title":"Development"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/ncb1963","article-title":"Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation","volume":"11","author":"Murakami","year":"2009","journal-title":"Nat Cell Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/1750-1172-8-154","article-title":"Deficiency for the ER-stress transducer OASIS causes severe recessive osteogenesis imperfecta in humans","volume":"8","author":"Symoens","year":"2013","journal-title":"Orphanet J Rare Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.7150\/thno.41378","article-title":"IL-23, but not IL-12, plays a critical role in inflammation-mediated bone disorders","volume":"10","author":"Xu","year":"2020","journal-title":"Theranostics"},{"key":"B46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/nyas.12059","article-title":"Role of PI3K\/Akt and mTOR complexes in Th17 cell differentiation","volume":"1280","author":"Nagai","year":"2013","journal-title":"Ann N Y Acad Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"102435","DOI":"10.1016\/j.jaut.2020.102435","article-title":"Selective targeting of PI3K\u03b4 suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases","volume":"111","author":"Chen","year":"2020","journal-title":"J Autoimmun"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.4049\/jimmunol.1103173","article-title":"Blockade of phosphatidylinositol 3-Kinase (PI3K)\u03b4 or PI3K\u03b3 Reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis","volume":"189","author":"Roller","year":"2012","journal-title":"J Immunol."},{"key":"B49","first-page":"101","volume-title":"Discovery of Pi3K Delta Inhibitors for the Treatment of Inflammatory and Autoimmune Disease","author":"Matthews","year":"2012"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.3389\/fimmu.2019.02344","article-title":"mTOR blockade by rapamycin in spondyloarthritis: impact on inflammation and new bone formation in vitro and in vivo","volume":"10","author":"Chen","year":"2020","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways in the regulation of cell proliferation in mammalian cells","volume":"12","author":"Wei","year":"2002","journal-title":"Cell Res."},{"key":"B52","first-page":"96","article-title":"Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment","volume":"26","author":"Lories","year":"2008","journal-title":"Clin Exp Rheumatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/ard.2010.143529","article-title":"Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR\/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as th","volume":"71","author":"De Launay","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.1158\/0008-5472.CAN-17-0579","article-title":"ANGPTL1 interacts with integrin \u03b11\u03b21 to suppress HCC angiogenesis and metastasis by inhibiting JAK2\/STAT3 signaling","volume":"77","author":"Yan","year":"2017","journal-title":"Cancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7888\/juoeh.41.317","article-title":"The roles of ANGPTL families in cancer progression","volume":"41","author":"Endo","year":"2019","journal-title":"J UOEH."},{"key":"B56","doi-asserted-by":"publisher","first-page":"7525","DOI":"10.1111\/jcmm.14621","article-title":"NOV\/CCN3 induces cartilage protection by inhibiting PI3K\/AKT\/mTOR pathway","volume":"23","author":"Huang","year":"2019","journal-title":"J Cell Mol Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.joca.2014.12.012","article-title":"Targeted mutation of NOV\/CCN3 in mice disrupts joint homeostasis and causes osteoarthritis-like disease","volume":"23","author":"Roddy","year":"2015","journal-title":"Osteoarthr Cartil"},{"key":"B58","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.canlet.2018.12.009","article-title":"Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer","volume":"444","author":"Takeda","year":"2019","journal-title":"Cancer Lett"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4062\/biomolther.2012.097","article-title":"Polyamines and their metabolites as diagnostic markers of human diseases","volume":"21","author":"Park","year":"2013","journal-title":"Biomol Ther."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.611656\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T10:55:46Z","timestamp":1614855346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.611656\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":59,"alternative-id":["10.3389\/fimmu.2021.611656"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.611656","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"article-number":"611656"}}